SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present data from a clinical trial studying Tyvaso...

Tyvaso® (treprostinil) Inhalation Solution net revenue growth of 29% year over year; total net revenue growth of 23% year over yearTyvaso DPI™ NDA under review with FDA action expected in October 2021 SILVER SPRING, Md...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2021 financial results before the...

Forced vital capacity improvement observed during the INCREASE study in patients with idiopathic pulmonary fibrosis represents the basis of the TETON registration study of Tyvaso in IPF SILVER SPRING, Md. and RESEARCH...

FDA action expected in October 2021 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 16, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 7, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation...

First pivotal study of Tyvaso® (treprostinil) Inhalation Solution outside pulmonary hypertension SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 3, 2021 /PRNewswire/ -- United Therapeutics Corporation...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 25, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United...

Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD)Tyvaso DPI™ New Drug Application (NDA) submitted to U.S. Food and Drug AdministrationTETON...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 26, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2021 financial results before the...

NDA submission includes both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease indicationsPriority review voucher applied to the NDA submission ...